Arcus Biosciences Inc

NYSE:RCUSUnited States

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately five clinical programs that are focused on targets, including TIGIT, PD-1, HIF-2a, adenosine A2a and A2b receptors and CD73. It is evaluating three antibodies and three small molecules across 13 different clinical studies, including four Phase III studies. It is developing two investigational anti-TIGIT monoclonal antibodies, which include domvanalimab (Fc-silent) and AB308 (Fc-enabled). HIF-2a is a master transcriptional regulator of multiple genes involved in tumor progression. The Company's investigational products also include etrumadenant and quemliclustat.

Contact Information

Headquarters

3928 Point Eden WayHAYWARD, CA, United States 94545-3719

Phone

510-694-6200

Fax

302-730-1370

Executives

Chairman of the Board, Chief Executive Officer, Co-Founder

Terry Rosen

Co-Founder, Director

Juan Jaen

Chief Financial Officer

Robert Goeltz

Chief Operating Officer, Director

Jennifer Jarrett

Chief Accounting Officer

Alexander Azoy